Human cancer regression antigens

Current Opinion in Immunology

Volumn 25, Issue 2, 2013, Pages 284-290

  Kvistborg, Pia ^a   van Buuren, Marit M ^a   Schumacher, Ton N ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 100; MAJOR HISTOCOMPATIBILITY ANTIGEN; MART I PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; BINDING AFFINITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTIC INFILTRATION; REVIEW;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84877085288     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.03.005     Document Type: Review

References (48)

1. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
2. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
3. Dudley M.E., Gross C.A., Langhan M.M., Garcia M.R., Sherry R.M., Yang J.C., Phan G.Q., Kammula U.S., Hughes M.S., Citrin D.E., et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010, 16:6122-6131.
4. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
5. Novellino L., Castelli C., Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005, 54:187-207.
6. Andersen R.S., Thrue C.A., Junker N., Lyngaa R., Donia M., Ellebaek E., Svane I.M., Schumacher T.N., Thor Straten P., Hadrup S.R. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012, 72:1642-1650.
7. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999, 11:263-270.
8. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997, 94:1914-1918.
9. Coulie P.G., Brichard V., Van Pel A., Wolfel T., Schneider J., Traversari C., Mattei S., De Plaen E., Lurquin C., Szikora J.P., et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994, 180:35-42.
10. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Rivoltini L., Topalian S.L., Miki T., Rosenberg S.A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994, 91:3515-3519.
11. Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A., Rose E.A., Kral A., Yeger H., Lewis W.H., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520.
12. Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D., Wolfel C., Huber C., Wolfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005, 102:16013-16018.
13. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer Zum Buschenfelde K.H., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284.
14. Kvistborg P., Shu C.J., Heemskerk B., Fankhauser M., Thrue C.A., Toebes M., van Rooij N., Linnemann C., van Buuren M.M., Urbanus J.H., et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012, 1:409-418.
15. Iacopetta B., Grieu F., Amanuel B. Microsatellite instability in colorectal cancer. Asia Pac J Clin Oncol 2010, 6:260-269.
16. Shima K., Morikawa T., Yamauchi M., Kuchiba A., Imamura Y., Liao X., Meyerhardt J.A., Fuchs C.S., Ogino S. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS ONE 2011, 6:e25062.
17. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
18. Yang B., O'Herrin S.M., Wu J., Reagan-Shaw S., Ma Y., Bhat K.M., Gravekamp C., Setaluri V., Peters N., Hoffmann F.M., et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007, 67:9954-9962.
19. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., Rodolfo M., Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 2006, 103:11160-11165.
20. Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005, 122:835-847.
21. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
22. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
23. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
24. Spiotto M.T., Rowley D.A., Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004, 10:294-298.
25. Wolkers M.C., Brouwenstijn N., Bakker A.H., Toebes M., Schumacher T.N. Antigen bias in T cell cross-priming. Science 2004, 304:1314-1317.
26. Schumacher T.N., Gerlach C., van Heijst J.W. Mapping the life histories of T cells. Nat Rev Immunol 2010, 10:621-631.
27. Landsberg J., Kohlmeyer J., Renn M., Bald T., Rogava M., Cron M., Fatho M., Lennerz V., Wolfel T., Holzel M., et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012, 490:412-416.
28. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
29. Hofmann O., Caballero O.L., Stevenson B.J., Chen Y.T., Cohen T., Chua R., Maher C.A., Panji S., Schaefer U., Kruger A., et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 2008, 105:20422-20427.
30. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924.
31. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
32. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., Davis J.L., Morgan R.A., Merino M.J., Sherry R.M., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011, 19:620-626.
33. Bos R., van Duikeren S., Morreau H., Franken K., Schumacher T.N., Haanen J.B., van der Burg S.H., Melief C.J., Offringa R. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008, 68:8446-8455.
34. Benlalam H., Labarriere N., Linard B., Derre L., Diez E., Pandolfino M.C., Bonneville M., Jotereau F. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur J Immunol 2001, 31:2007-2015.
35. Toebes M., Coccoris M., Bins A., Rodenko B., Gomez R., Nieuwkoop N.J., van de Kasteele W., Rimmelzwaan G.F., Haanen J.B., Ovaa H., et al. Design and use of conditional MHC class I ligands. Nat Med 2006, 12:246-251.
36. Hadrup S.R., Bakker A.H., Shu C.J., Andersen R.S., van Veluw J., Hombrink P., Castermans E., Thor Straten P., Blank C., Haanen J.B., et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009, 6:520-526.
37. Newell E.W., Klein L.O., Yu W., Davis M.M. Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 2009, 6:497-499.
38. Andersen R.S., Kvistborg P., Frosig T.M., Pedersen N.W., Lyngaa R., Bakker A.H., Shu C.J., Straten P., Schumacher T.N., Hadrup S.R. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 2012, 7:891-902.
39. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012.
40. Baren N., Baurain J.-F., Brasseur F., Coulie P.G. Melanoma antigens recognized by T lymphocytes. Targeted Therapeutics in Melanoma 2012, 187-205. Springer New York, New York.
41. Heemskerk B., Kvistborg P., Schumacher T.N. The cancer antigenome. EMBO J 2012, 32:194-203.
42. Castle J.C., Kreiter S., Diekmann J., Lower M., van de Roemer N., de Graaf J., Selmi A., Diken M., Boegel S., Paret C., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012, 72:1081-1091.
43. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
44. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJA, Behjati S, Hilkmann H, el Atmioui D et al.: Tumor exome analysis reveals neo-antigen-specific T cell reactivity in an Ipilimumab-responsive melanoma. J Clin Oncol 2013, in press.
45. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
46. Jager E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jager D., Arand M., Wada H., Noguchi Y., Stockert E., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998, 187:265-270.
47. Nakagawa M., Stites D.P., Farhat S., Sisler J.R., Moss B., Kong F., Moscicki A.B., Palefsky J.M. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997, 175:927-931.
48. Bellantuono I., Gao L., Parry S., Marley S., Dazzi F., Apperley J., Goldman J.M., Stauss H.J. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002, 100:3835-3837.